学校法人順天堂　研究者情報データベース:::研究業績詳細:::

HOME　＞　研究業績詳細

研究業績詳細

森本幾夫（モリモトチカオ）

研究テーマ	臨床免疫学／CD26分子の機能と構造及びその免疫病、がんへの先端治療開発
研究業績（論文）	Microscopic polyangiitis initiated with liver dysfunction, calf pain and fever of unknown origin.: Ohnuma K, Hosono O, Katayose T, Yoshikawa N, Kawasaki H, Fujii T, Oyaizu N, Tanaka H, Morimoto C.: Rheumatol Int.: 2010: 30: 1651-6. Aqueous extract of Carica papaya leaves exhibits anti-tumor activity and immunomodulatory effects.: Otsuki N, Dang NH, Kumagai E, Kondo A, Iwata S, Morimoto C.: J Ethnopharmacol.: 2010: 127: 760-7. Optimal stimulation for CD70 induction on human monocyte-derived dendritic cells and the importance of CD70 in naive CD4(+) T-cell differentiation.: Arimoto-Miyamoto K, Kadowaki N, Kitawaki T, Iwata S, Morimoto C, Uchiyama T.: Immunology.: 2010: 130: 137-49. Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines.: Takasawa W, Ohnuma K, Hatano R, Endo Y, Dang NH, Morimoto C.: Biochem Biophys Res Commun.: 2010: 401: 7-12. Identification of cancer stem cell markers in human malignant mesothelioma cells.: Ghani FI, Yamazaki H, Iwata S, Okamoto T, Aoe K, Okabe K, Mimura Y, Fujimoto N, Kishimoto T, Yamada T, Xu CW, Morimoto C.: Biochem Biophys Res Commun.: 2011: 404: 735-42. Mechanisms of confluence-dependent expression of CD26 in colon cancer cell lines.: Abe M, Havre PA, Urasaki Y, Ohnuma K , Morimoto C, Dang LH, Dang NH.: BMC Cancer.: 2011: 11: 51. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle.: Shimizu N, Yoshikawa N, Ito N, Maruyama T, Suzuki Y, Takeda S, Nakae J, Tagata Y, Nishitani S, Takehana K, Sano M, Fukuda K, Suematsu M, Morimoto C, Tanaka H.: Cell Metab.: 2011: 13: 170-82. Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice.: Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M, Sakamoto E, Koganei M, Sasaki H, Nagashima Y, Amo K, Aoki K, Morimoto C, Takeda E, Terauchi Y.: Diabetes.: 2011: 60: 1246-57. Regulation of cancer stem cell properties by CD9 in human B-acute lymphoblastic leukemia.: Yamazaki H, Wilson Xu C, Naito M, Nishida H, Okamoto T, Ghani FI, Iwata S, Inukai T, Sugita K, Morimoto C.: Biochem Biophys Res Commun.: 2011: 409: 14-21. Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines.: Amatya VJ, Takeshima Y, Kushitani K, Yamada T, Morimoto C, Inai K.: Oncol Rep.: 2011: 26: 1369-1375. CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma.: Aoe K, Amatya VJ, Fujimoto N, Ohnuma K, Hosono O, Hiraki A, Fujii M, Yamada T, Dang NH, Takeshima Y, Inai K, Kishimoto T, and Morimoto C.: Clin Cancer Res.: 2012: 18: 1447-1456. Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells.: Yamazaki H, Naito M, Ghani FI, Dang NH, Iwata S, Morimoto C.: Biochem Biophys Res Commun.: 2012: 419: 529-36. Impact of the Integrin Signaling Adaptor Protein NEDD9 on Prognosis and Metastatic Behavior of Human Lung Cancer.: Kondo S, Iwata S, Yamada T, Inoue Y, Ichihara H, Kichikawa Y, Katayose T, Souta-Kuribara A, Yamazaki H, Hosono O, Kawasaki H, Tanaka H, Hayashi Y, Sakamoto M, Kamiya K, Dang NH, Morimoto C.: Clin Cancer Res.: 2012: 18: 6326-6338. Cardiomyocyte-Specific Overexpression of HEXIM1 Prevents Right Ventricular Hypertrophy in Hypoxia-Induced Pulmonary Hypertension in Mice.: Yoshikawa N, Shimizu N, Maruyama T, Sano M, Matsuhashi T, Fukuda K, Kataoka M, Satoh T, Ojima H, Sawai T, Morimoto C, Kuribara A, Hosono O, Tanaka H.: PLoS One.: 2012: 7: e2522. CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma.: Amatya VJ, Takeshima Y, Aoe K, Fujimoto N, Okamoto T, Yamada T, Kishimoto T, Morimoto C, Inai K.: Oncol Rep.: 2013: 29: 21-8. CD26-mediated costimulation in human CD8+T cells provokes effector function via proinflammatory cytokine production.: Hatano R, Ohnuma K, Yamamoto J, Komoriya K, Dang NH, Morimoto C.: Immunol.: 2013: 138: 165-72. Multiple effects of repetitive transcranial magnetic stimulation on neuropsychiatric disorders.: Ikeda T, Kurosawa M, Morimoto C, Kitayama S, Nukina N.: Biochem Biophys Res Commun.: 2013: 436: 121-7. Nuclear Localization of CD26 Induced by a Humanized Monoclonal Antibody Inhibits Tumor Cell Growth by Modulating of POLR2A Transcription.: Yamada K, Hayashi M, Madokoro H, Nishida H, Du W, Ohnuma K, Sakamoto M, Morimoto C, Yamada T.: PLoS One.: 2013: 8: e62304. Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody.: Hatano R, Ohnuma K, Yamamoto J, Dang NH, Yamada T, Morimoto C.: Br J Haematol.: 2013: 162: 263-77. Bilateral Entry and Release of Middle East Respiratory Syndrome-Coronavirus Induces Profound Apoptosis of Human Bronchial Epithelial Cells.: Tao X, Hill TE, Morimoto C, Peters CJ, Ksiazek TG, Tseng CT.: J Virol. 2013: 87: 9953-8. Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors.: Saito T, Ohnuma K, Suzuki H, Dang NH, Hatano R, Ninomiya H, Morimoto C.: Diabetes Res Clin Pract. 2013: 102: e8-e12. Inhibition of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection by Anti-CD26 Monoclonal Antibody.: Ohnuma K, Haagmans BL, Hatano R, Raj VS, Mou H, Iwata S, Dang NH, Bosch BJ, Morimoto C.: J Virol. 2013;87: 13892-9. CD26 Expression on T-Anaplastic Large Cell Lymphoma (ALCL) Line Karpas 299 is Associated with Increased Expression of Versican and MT1-MMP and Enhanced Adhesion.: Havre PA, Dang LH, Ohnuma K, Iwata S, Morimoto C, Dang NH.: 2013: 13: 517. CD9 Negatively Regulates CD26 Expression and Inhibits CD26-Mediated Enhancement of Invasive Potential of Malignant Mesothelioma cells:Okamoto T, Iwata S, Yamazaki H, Hatano R, Komiya E, Dang NH, Ohnuma K, Morimoto C :PLoS One. 2014; 9: e86671. Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue: Hatano R, Yamada T, Matsuoka S, Iwata S, Yamazaki H, Komiya E, Okamoto T, Dang NH, Ohnuma K, Morimoto C:Diagn Pathol. 2014; 9: 30. doi: 10.1186/1746-1596-9-30 Grassypeptolides as Natural Inhibitors of Dipeptidyl Peptidase 8 and T-Cell Activation :Kwan JC, Liu Y, Ratnayake R, Hatano R, Kuribara A, Morimoto C, Ohnuma K, Paul VJ, Ye T, Luesch H.:Chembiochem. 2014; 15:799-804. Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma:Yamamoto J, Ohnuma K, Hatano R, Okamoto T, Komiya E, Yamazaki H, Iwata S, Dang NH, Aoe K, Kishimoto T, Yamada T, Morimoto C:Br J Cancer. 2014; 110: 2232-2245 CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells: Komiya E, Ohnuma K,Yamazaki H, Hatano R, Iwata S, Okamoto T, Dang NH, Yamada T, Morimoto C:Biochem Biophys Res Commun. 2014; 4: 609–615 Blockade of CD26 Signaling Inhibits Human Osteoclast Development: Nishida H, Suzuki H, Madokoro H, Hayashi M, Morimoto C, Sakamoto M, Yamada T: J Bone Miner Res. 2014; 29: 2439–2455 Clinical significance of soluble CD26 in malignant pleural mesothelioma: Fujimoto N, Ohnuma K, Aoe K, Hosono O, Yamada T, Kishimoto T, Morimoto C:PLoS One. 2014; 9:e115647 CD26-mediated induction of EGR2 and IL-10 as potential regulatory mechanism for CD26 costimulatory pathway: Hatano R, Ohnuma K, Otsuka H, Komiya E, Taki I, Iwata S, Dang NH, Okumura K, Morimoto C: J Immunol. 2015; 194: 960-972. Comparison of two commercial ELISAs against an in-house ELISA for measuring soluble CD26 in human serum: Ohnuma K, Saito T, Hatano R, Hosono O, Iwata S, Dang NH, Ninomiya H, Morimoto C:J Clin Lab Anal. 2015; Mar;29:106-11. Regulation of pulmonary GVHD by IL-26+CD4 T lymphocytes through CD26/caveolin-1 interaction: Ohnuma K, Hatano R, Aune TM, Otsuka H, Iwata S, Dang NH, Yamada T, Morimoto C:J Immunol. 2015; 194:3697-3712 DPP4 in anti-tumor immunity:going beyond the enzyme: Ohnuma K, Hatano R, Morimoto C.:Nat Immunol. 2015;16:791-2. Modulation of immunological responses and amelioration of collagen-induced arthritis by the novel roxithromycin derivative 5-I.:Otsuki N, Iwata S, Yamada T, Hosono O, Dang NH, Hatano R, Ohnuma K, Morimoto C:Mod Rheumatol. 2015;25:562-70. The role of Cas-L/NEDD9 as a regulator of collagen-induced arthritis in a murine model.: Katayose T, Iwata S, Oyaizu N, Hosono O, Yamada T, Dang NH, Hatano R, Tanaka H, Ohnuma K, Morimoto C:Biochem Biophys Res Commun. 2015;460:1069-75. Inhibition of VEGF-dependent angiogenesis by the anti-CD82 monoclonal antibody 4F9 through regulation of lipid raft microdomains: Nomura S, Iwata S, Hatano R, Komiya E, Dang NH, Iwao N, Ohnuma K, MorimotoC: Biochem Biophys Res Commun.2016;20:111-7 A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition:Hayashi M, Madokoro H, Yamada K, Nishida H, Morimoto C, Sakamoto M, Yamada T:Cancer Cell Int.2016;30:16-35 Ikeda T, Fragiadaki M,Shi-wen Xu, Ponticos M, Khan K, Denton C, Garcia P, Bou-Gharios G, Yamakawa A, Morimoto C, Abraham D. Transforming growth factor-β-induced CUX1 isoforms are associated with fibrosis in systemic sclerosis lung fibroblasts. Biochemistry and Biophysics Reports.2016;7:246-252. Mizutani N, Abe M, Matsuoka S, Kajino K, Wakiya M, Ohtsuji N, Hatano R, Morimoto C, Hino O. Establishment of anti-mesothelioma monoclonal antibodies. BMC Res Notes.2016;9:324. Omata Y, Nakamura S ,Koyama T, Yasui T, Hirose J, Izawa N, Matsumoto T, Imai Y, Seo S, Kurokawa M, Tsutsumi S, Kadono Y, Morimoto C, Aburatani H, Miyamoto T, Tanaka S. Identification of Nedd9 as a TGF-β-Smad2/3 Target Gene Involved in RANKL-induced Osteoclastogenesis by Comprehensive Analysis. PLoS One.2016; 11:e0157992. Ohnuma K, Hatano R, Itoh T, Iwao N, Dang NH, Morimoto C. Role of IL-26+CD26+CD4 T Cells in Pulmonary chronic graft-versus-host disease and treatment with Caveolin-1-Ig Fc conjugate. Crit Rev Immunol.2016;36:239-267. Doonan BP, Ohnuma K, Dang LH, Morimoto C, Dang NH. Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target. Curr Cancer Ther Rev.2017;13:1-13. Angevin E, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcman G, Vielh P, Farace F, Valleix F, Podoll T, Kuramochi Y, Miyashita I, Hosono O, Dang NH, Ohnuma K, Yamada T, Kaneko Y, Morimoto C. First-in-Human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers. Br J Cancer.2017;116:1126-1134. Komiya E, Hatano R, Otsuka H, Itoh T, Yamazaki H, Yamada T, Dang NH, Tominaga M, Suga Y, Kimura U, Takamori K, Morimoto C, Ohnuma K. A possible role for CD26/DPPIV enzyme activity in the regulation of psoriatic pruritus. J Dermatol Sci.2017;86:212-221. Kim KM, Noh JH, Bodogai M, Martindale JL, Yang X, Indig FE, Basu SK, Ohnuma K, Morimoto C, Johnson PF, Biragyn A, Abdelmohsen K, Gorospe M. Identification of senescent cell surface targetable protein DDP4.Genes Dev.2017;31:1529-1534. Ohnuma K, Hatano R, Yamazaki H, Kaneko Y, Dang NH, Morimoto C. CD26-targeted therapy: A new horizon in malignant pleural mesothelioma management. In: Horizons in Cancer Research, Nova Science Publishers, Inc., Hauppauge, NY, Editor: Hiroto S. Watanabe.2017; Volume 64: Chapter 6:129-162. Hatano R, Ohnuma K, Yamada T, Okamoto T, Komiya E, Otsuka H, Itoh T, Yamazaki H, Iwao N, Kaneko Y, Dang NH, Morimoto C. The use of the humanized anti-CD26 monoclonal antibody YS110 as a novel targeted therapy for refractory cancers and immune disorders. In: Advances in Medicine and Biology, Nova Science Publishers, Inc., Hauppauge, NY, Editor: Leon V. Berhardt.2018;Volume 129: Chapter 1:1-44. Ohnuma K, Hatano R, Komiya E, Otsuka H, Itoh T, Iwao N, Kaneko Y, Yamada T, Dang NH, Morimoto C. A novel role for CD26/dipeptidyl peptidase IV as a therapeutic target. Front Biosci.2018;23:1754-1779. Okamoto T, Yamazaki H, Hatano R, Yamada T, Kaneko Y, Xu CW, Dang NH, Ohnuma K, Morimoto C. Targeting CD26 suppresses proliferation of malignant mesothelioma cell via downmodulation of ubiquitin-specific protease 22. Biochem Biophys Res Commun. 2018; 504(2): 491-498 Nishida H, Hayashi M, Morimoto C, Sakamoto M, Yamada T.CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma. Blood Cancer J. 2018; 8(11): 99 Ohnuma K, Hatano R, Komiya E, Otsuka H, Itoh T, Iwao N, Kaneko Y, Yamada T, Dang NH, Morimoto C. A novel role for CD26/dipeptidyl peptidase IV as a therapeutic target. Front Biosci(Landmark Ed). 2018;23:1754-1779 Ohnuma K, Hatano R, Dang NH, Morimoto C. Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy. Mod Rheumatol. 2018;Oct 4:1-32[Epub ahead of print] Itoh T, Hatano R, Komiya E, Otsuka H, Narita Y, Aune TM, Dang NH, Matsuoka S, Naito H, Tominaga M, Takamori K, Morimoto C, Ohnuma K. Biological effects of IL-26 on T cell-mediated skin inflammation including psoriasis. J Invest Dermatol. 2019; 139(4): 878-889 Santos MF, Rappa G, Karbanova J, Vanier C, Morimoto C, Corbeil D, Lorico A. Anti-human CD9 antibody Fab fragment impairs the internalization of extracellular vesicles and the nuclear transfer of their cargo proteins. J Cell Mol Med. 2019; 23(6): 4408-4421 Mezawa Y, Daigo Y, Takano A, Miyagi Y, Yokose T, Yamashita T, Morimoto C, Hino O, Orimo A. CD26 expression is attenuated by TGF-β and SDF-1 autocrine signaling on stromal myofibroblasts in human breast cancers. Cancer Med. 2019; 8(8): 3936-3948 Hatano R, Yamada T, Madokoro H, Otsuka H, Komiya E, Itoh T, Narita Y, Iwata S, Yamazaki H, Matsuoka S, Dang NH, Ohnuma K, Morimoto C. Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens. PLoS One. 2019; 14(6): e0218330 Hatano R, Itoh T, Otsuka H, Okamoto S, Komiya E, Iwata S, Aune TM, Dang NH, Kuwahara-Arai K, Ohnuma K, Morimoto C. Characterization of novel anti-IL-26 neutralizing monoclonal antibodies for the treatment of inflammatory diseases including psoriasis. MAbs. 2019; 11(8): 1428-1442 Hayashi M, Madokoro H, Yamada K, Nishida H, Morimoto C, Sakamoto M, Yanagawa H, Yamada T. Novel Antibody-Drug Conjugate with Anti-CD26 Humanized Monoclonal Antibody and Transcription Factor IIH(TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis. Cancers (Basel). 2019; 11(8): E1138 Takeda T, Ohe Y, Horinouchi H, Hida T, Shimizu J, Seto T, Nosaki K, Kishimoto T, Miyashita I, Yamada M, Kaneko Y, Morimoto C, Nakagawa K. Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma. Lung Cancer 2019 Sep 16; 137:64-70 Sato T, Tatekoshi A, Takada K, Iyama S, Kamihara Y, Jawaid P, Rehman MU, Noguchi K, Kondo T, Kajikawa S, Arita K, Wada A, Murakami J, Arai M, Yasuda I, Dang NH, Hatano R, Iwao N, Ohnuma K, Morimoto C. DPP8 is a novel therapeutic target for multiple myeloma. Sci Rep. 2019; 9(1):18094 Corridoni　D, Antanaviciute A, Gupta T, Fawkner-Corbett D, Aulicino A, Jagielowicz M, Parikh K, Repapi E, Taylor S, Ishikawa D, Hatano R, Yamada T, Xin W, Slawinski H, Bowden R, Napolitani G, Brain O, Morimoto C, Koohy H, Simmons A. Single-cell atlas of colonic CD8+ T cells in ulcerative colitis. Nat Med. 2020;26(9):1480-1490 Kaneko Y, Hatano R, Hirota N, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcman G, Valleix F, Podoll T, Umezawa Y, Takao S, Iwata S, Hosono O, Taguchi T, Yamada T, Dang NH, Ohnuma K, Angevin E, Morimoto C. Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.　 Biomark Res. 2021;9(1):21 Itoh T, Hatano R, Horimoto Y, Yamada T, Song D, Otsuka H, Shirakawa Y, Matsuoka S, Iwao N, Aune TM, Dang NH, Kaneko Y, Okumura K, Morimoto C, Ohnuma K. IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells. Cell Death Dis. 2021; 12(6): 520 Pan K, Ohnuma K, Morimoto C, Dang NH. CD26/Dipeptidyl Peptidase IV and Its Multiple Biological Functions. Cureus. 2021; 13(2): e13495 Ohmachi-Ono A, Yamada S, Uno S, Tamai M, Soga K, Nakamura S, Udagawa N, Nakamichi Y, Koide M, Morita Y, Takano T, Itoh T, Kakuta S, Morimoto C, Matsuoka S, Iwakura Y, Tomura M, Kiyono H, Hachimura S, Nakajima-Adachi H. Effector memory CD4 + T cells in mesenteric lymph nodes mediate bone loss in food-allergic enteropathy model mice, creating IL-4 dominance. Mucosal Immunol. 2021; 14(6):1335-1346 Komiya E, Mitsutoshi Tominaga M, Hatano R, kamikubo Y, Toyama S, Sakairi H, Hond K, Itoh T, Kamata Y, Tsurumachi M, Kishi R, Ohnuma K, Sakurai T, Morimoto C, Takamori K. Peripheral endomorphins drive mechanical alloknesis under the enzymatic control of CD26/DPPIV. J Allergy Clin Immunol. 2022;149(3):1085-1096 Hatano R, Itoh T, Otsuka H, Saeki H, Yamamoto A, Song D, Shirakawa Y, Iyama S, Sato T, Iwao N, Harada N, Aune TM, Dang NH, Kaneko Y, Yamada T, Morimoto C, Ohnuma K. Humanized anti-IL-26 monoclonal antibody as a novel targeted therapy for chronic graft-versus-host disease. Am J Transplant. 2022; 22(12): 2804-2820. doi: 10.1111/atj.17178. Epub 2022 Sep 9. Santos MF, Rappa G, Fontana S, Karbanova J, Aalam F, Tai D, Li Z, Pucci M, Alessandro R, Morimoto C, Corbeil D, Lorico A. Anti-Human CD9 Fab Fragment Antibody Blocks the Extracellular Vesicle-Mediated Increase in Malignancy of Colon Cancer Cells. Cells. 2022; 11(16):2474. doi: 10.3390/cells11162474. Kobayashi S, Fugo K, Hatano R, Yamazaki K, Morimoto C, Terawaki H. Anti-glomerular Basement Membrane Disease Concomitant with MPO-ANCA Positivity Concurrent with High Serum Levels of Interleukin-26 Following Coronavirus Disease 2019 Vaccination. Intern Med. 2023; 62(7): 1043-1048. Doi: 10.2169/internalmedicine.1027-22. Koyanagi Y, Kawasaki T, Kasuya Y, Hatano R, Sato S, Takahashi Y, Ohnuma K, Morimoto C, Dudek SM, Tatsumi K, Suzuki T. Functional roles of CD26/DPP4 in bleomycin-induced pulmonary fibrosis. Physiol Rep. 2023; 11(6): e15645. Doi: 10.14814/phy2.15645. Kikuchi S, Wada A, Kamihara Y, Okazaki K, Jawaid P, Rehman MU, Kobayashi E, Susukida T, Minemura T, Nabe Y, Iwao N, Ozawa T, Hatano R, Yamada M, Kishi H, Matsuya Y, Mizuguchi M, Hayakawa Y, Dang NH, Sakamoto Y, Morimoto C, Sato T. DPP8 Selective Inhibitor Tominostat as a Novel and Broad-Spectrum Anticancer Agent against Hematological Malignancies. Cells. 2023; 12(7): 1100. Doi: 10.3390/cells12071100.

研究テーマ

臨床免疫学／CD26分子の機能と構造及びその免疫病、がんへの先端治療開発

研究業績（論文）

Microscopic polyangiitis initiated with liver dysfunction, calf pain and fever of unknown origin.: Ohnuma K, Hosono O, Katayose T, Yoshikawa N, Kawasaki H, Fujii T, Oyaizu N, Tanaka H, Morimoto C.: Rheumatol Int.: 2010: 30: 1651-6.

Aqueous extract of Carica papaya leaves exhibits anti-tumor activity and immunomodulatory effects.: Otsuki N, Dang NH, Kumagai E, Kondo A, Iwata S, Morimoto C.: J Ethnopharmacol.: 2010: 127: 760-7.

Optimal stimulation for CD70 induction on human monocyte-derived dendritic cells and the importance of CD70 in naive CD4(+) T-cell differentiation.: Arimoto-Miyamoto K, Kadowaki N, Kitawaki T, Iwata S, Morimoto C, Uchiyama T.: Immunology.: 2010: 130: 137-49.

Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines.: Takasawa W, Ohnuma K, Hatano R, Endo Y, Dang NH, Morimoto C.: Biochem Biophys Res Commun.: 2010: 401: 7-12.

Identification of cancer stem cell markers in human malignant mesothelioma cells.: Ghani FI, Yamazaki H, Iwata S, Okamoto T, Aoe K, Okabe K, Mimura Y, Fujimoto N, Kishimoto T, Yamada T, Xu CW, Morimoto C.: Biochem Biophys Res Commun.: 2011: 404: 735-42.

Mechanisms of confluence-dependent expression of CD26 in colon cancer cell lines.: Abe M, Havre PA, Urasaki Y, Ohnuma K , Morimoto C, Dang LH, Dang NH.: BMC Cancer.: 2011: 11: 51.

Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle.: Shimizu N, Yoshikawa N, Ito N, Maruyama T, Suzuki Y, Takeda S, Nakae J, Tagata Y, Nishitani S, Takehana K, Sano M, Fukuda K, Suematsu M, Morimoto C, Tanaka H.: Cell Metab.: 2011: 13: 170-82.

Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice.: Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M, Sakamoto E, Koganei M, Sasaki H, Nagashima Y, Amo K, Aoki K, Morimoto C, Takeda E, Terauchi Y.: Diabetes.: 2011: 60: 1246-57.

Regulation of cancer stem cell properties by CD9 in human B-acute lymphoblastic leukemia.: Yamazaki H, Wilson Xu C, Naito M, Nishida H, Okamoto T, Ghani FI, Iwata S, Inukai T, Sugita K, Morimoto C.: Biochem Biophys Res Commun.: 2011: 409: 14-21.

Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines.: Amatya VJ, Takeshima Y, Kushitani K, Yamada T, Morimoto C, Inai K.: Oncol Rep.: 2011: 26: 1369-1375.

CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma.: Aoe K, Amatya VJ, Fujimoto N, Ohnuma K, Hosono O, Hiraki A, Fujii M, Yamada T, Dang NH, Takeshima Y, Inai K, Kishimoto T, and Morimoto C.: Clin Cancer Res.: 2012: 18: 1447-1456.

Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells.: Yamazaki H, Naito M, Ghani FI, Dang NH, Iwata S, Morimoto C.: Biochem Biophys Res Commun.: 2012: 419: 529-36.

Impact of the Integrin Signaling Adaptor Protein NEDD9 on Prognosis and Metastatic Behavior of Human Lung Cancer.: Kondo S, Iwata S, Yamada T, Inoue Y, Ichihara H, Kichikawa Y, Katayose T, Souta-Kuribara A, Yamazaki H, Hosono O, Kawasaki H, Tanaka H, Hayashi Y, Sakamoto M, Kamiya K, Dang NH, Morimoto C.: Clin Cancer Res.: 2012: 18: 6326-6338.

Cardiomyocyte-Specific Overexpression of HEXIM1 Prevents Right Ventricular Hypertrophy in Hypoxia-Induced Pulmonary Hypertension in Mice.: Yoshikawa N, Shimizu N, Maruyama T, Sano M, Matsuhashi T, Fukuda K, Kataoka M, Satoh T, Ojima H, Sawai T, Morimoto C, Kuribara A, Hosono O, Tanaka H.: PLoS One.: 2012: 7: e2522.

CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma.: Amatya VJ, Takeshima Y, Aoe K, Fujimoto N, Okamoto T, Yamada T, Kishimoto T, Morimoto C, Inai K.: Oncol Rep.: 2013: 29: 21-8.

CD26-mediated costimulation in human CD8+T cells provokes effector function via proinflammatory cytokine production.: Hatano R, Ohnuma K, Yamamoto J, Komoriya K, Dang NH, Morimoto C.: Immunol.: 2013: 138: 165-72.

Multiple effects of repetitive transcranial magnetic stimulation on neuropsychiatric disorders.: Ikeda T, Kurosawa M, Morimoto C, Kitayama S, Nukina N.: Biochem Biophys Res Commun.: 2013: 436: 121-7.

Nuclear Localization of CD26 Induced by a Humanized Monoclonal Antibody Inhibits Tumor Cell Growth by Modulating of POLR2A Transcription.: Yamada K, Hayashi M, Madokoro H, Nishida H, Du W, Ohnuma K, Sakamoto M, Morimoto C, Yamada T.: PLoS One.: 2013: 8: e62304.

Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody.: Hatano R, Ohnuma K, Yamamoto J, Dang NH, Yamada T, Morimoto C.: Br J Haematol.: 2013: 162: 263-77.

Bilateral Entry and Release of Middle East Respiratory Syndrome-Coronavirus Induces Profound Apoptosis of Human Bronchial Epithelial Cells.: Tao X, Hill TE, Morimoto C, Peters CJ, Ksiazek TG, Tseng CT.: J Virol. 2013: 87: 9953-8.

Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors.: Saito T, Ohnuma K, Suzuki H, Dang NH, Hatano R, Ninomiya H, Morimoto C.: Diabetes Res Clin Pract. 2013: 102: e8-e12.

Inhibition of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection by Anti-CD26 Monoclonal Antibody.: Ohnuma K, Haagmans BL, Hatano R, Raj VS, Mou H, Iwata S, Dang NH, Bosch BJ, Morimoto C.: J Virol. 2013;87: 13892-9.

CD26 Expression on T-Anaplastic Large Cell Lymphoma (ALCL) Line Karpas 299 is Associated with Increased Expression of Versican and MT1-MMP and Enhanced Adhesion.: Havre PA, Dang LH, Ohnuma K, Iwata S, Morimoto C, Dang NH.: 2013: 13: 517.

CD9 Negatively Regulates CD26 Expression and Inhibits CD26-Mediated Enhancement of Invasive Potential of Malignant Mesothelioma cells:Okamoto T, Iwata S, Yamazaki H, Hatano R, Komiya E, Dang NH, Ohnuma K, Morimoto C :PLoS One. 2014; 9: e86671.

Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue: Hatano R, Yamada T, Matsuoka S, Iwata S, Yamazaki H, Komiya E, Okamoto T, Dang NH, Ohnuma K, Morimoto C:Diagn Pathol. 2014; 9: 30. doi: 10.1186/1746-1596-9-30

Grassypeptolides as Natural Inhibitors of Dipeptidyl Peptidase 8 and T-Cell Activation :Kwan JC, Liu Y, Ratnayake R, Hatano R, Kuribara A, Morimoto C, Ohnuma K, Paul VJ, Ye T, Luesch H.:Chembiochem. 2014; 15:799-804.

Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma:Yamamoto J, Ohnuma K, Hatano R, Okamoto T, Komiya E, Yamazaki H, Iwata S, Dang NH, Aoe K, Kishimoto T, Yamada T, Morimoto C:Br J Cancer. 2014; 110: 2232-2245

CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells: Komiya E, Ohnuma K,Yamazaki H, Hatano R, Iwata S, Okamoto T, Dang NH, Yamada T, Morimoto C:Biochem Biophys Res Commun. 2014; 4: 609–615

Blockade of CD26 Signaling Inhibits Human Osteoclast Development: Nishida H, Suzuki H, Madokoro H, Hayashi M, Morimoto C, Sakamoto M, Yamada T: J Bone Miner Res. 2014; 29: 2439–2455

Clinical significance of soluble CD26 in malignant pleural mesothelioma: Fujimoto N, Ohnuma K, Aoe K, Hosono O, Yamada T, Kishimoto T, Morimoto C:PLoS One. 2014; 9:e115647

CD26-mediated induction of EGR2 and IL-10 as potential regulatory mechanism for CD26 costimulatory pathway: Hatano R, Ohnuma K, Otsuka H, Komiya E, Taki I, Iwata S, Dang NH, Okumura K, Morimoto C: J Immunol. 2015; 194: 960-972.

Comparison of two commercial ELISAs against an in-house ELISA for measuring soluble CD26 in human serum: Ohnuma K, Saito T, Hatano R, Hosono O, Iwata S, Dang NH, Ninomiya H, Morimoto C:J Clin Lab Anal. 2015; Mar;29:106-11.

Regulation of pulmonary GVHD by IL-26+CD4 T lymphocytes through CD26/caveolin-1 interaction: Ohnuma K, Hatano R, Aune TM, Otsuka H, Iwata S, Dang NH, Yamada T, Morimoto C:J Immunol. 2015; 194:3697-3712

DPP4 in anti-tumor immunity:going beyond the enzyme: Ohnuma K, Hatano R, Morimoto C.:Nat Immunol. 2015;16:791-2.

Modulation of immunological responses and amelioration of collagen-induced arthritis by the novel roxithromycin derivative 5-I.:Otsuki N, Iwata S, Yamada T, Hosono O, Dang NH, Hatano R, Ohnuma K, Morimoto C:Mod Rheumatol. 2015;25:562-70.

The role of Cas-L/NEDD9 as a regulator of collagen-induced arthritis in a murine model.: Katayose T, Iwata S, Oyaizu N, Hosono O, Yamada T, Dang NH, Hatano R, Tanaka H, Ohnuma K, Morimoto C:Biochem Biophys Res Commun. 2015;460:1069-75.

Inhibition of VEGF-dependent angiogenesis by the anti-CD82 monoclonal antibody 4F9 through regulation of lipid raft microdomains: Nomura S, Iwata S, Hatano R, Komiya E, Dang NH, Iwao N, Ohnuma K, MorimotoC: Biochem Biophys Res Commun.2016;20:111-7

A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition:Hayashi M, Madokoro H, Yamada K, Nishida H, Morimoto C, Sakamoto M, Yamada T:Cancer Cell Int.2016;30:16-35

Ikeda T, Fragiadaki M,Shi-wen Xu, Ponticos M, Khan K, Denton C, Garcia P, Bou-Gharios G, Yamakawa A, Morimoto C, Abraham D. Transforming growth factor-β-induced CUX1 isoforms are associated with fibrosis in systemic sclerosis lung fibroblasts. Biochemistry and Biophysics Reports.2016;7:246-252.

Mizutani N, Abe M, Matsuoka S, Kajino K, Wakiya M, Ohtsuji N, Hatano R, Morimoto C, Hino O. Establishment of anti-mesothelioma monoclonal antibodies. BMC Res Notes.2016;9:324.

Omata Y, Nakamura S ,Koyama T, Yasui T, Hirose J, Izawa N, Matsumoto T, Imai Y, Seo S, Kurokawa M, Tsutsumi S, Kadono Y, Morimoto C, Aburatani H, Miyamoto T, Tanaka S. Identification of Nedd9 as a TGF-β-Smad2/3 Target Gene Involved in RANKL-induced Osteoclastogenesis by Comprehensive Analysis. PLoS One.2016; 11:e0157992.

Ohnuma K, Hatano R, Itoh T, Iwao N, Dang NH, Morimoto C. Role of IL-26+CD26+CD4 T Cells in Pulmonary chronic graft-versus-host disease and treatment with Caveolin-1-Ig Fc conjugate. Crit Rev Immunol.2016;36:239-267.

Doonan BP, Ohnuma K, Dang LH, Morimoto C, Dang NH. Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target. Curr Cancer Ther Rev.2017;13:1-13.

Angevin E, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcman G, Vielh P, Farace F, Valleix F, Podoll T, Kuramochi Y, Miyashita I, Hosono O, Dang NH, Ohnuma K, Yamada T, Kaneko Y, Morimoto C. First-in-Human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers. Br J Cancer.2017;116:1126-1134.

Komiya E, Hatano R, Otsuka H, Itoh T, Yamazaki H, Yamada T, Dang NH, Tominaga M, Suga Y, Kimura U, Takamori K, Morimoto C, Ohnuma K. A possible role for CD26/DPPIV enzyme activity in the regulation of psoriatic pruritus. J Dermatol Sci.2017;86:212-221.

Kim KM, Noh JH, Bodogai M, Martindale JL, Yang X, Indig FE, Basu SK, Ohnuma K, Morimoto C, Johnson PF, Biragyn A, Abdelmohsen K, Gorospe M. Identification of senescent cell surface targetable protein DDP4.Genes Dev.2017;31:1529-1534.

Ohnuma K, Hatano R, Yamazaki H, Kaneko Y, Dang NH, Morimoto C. CD26-targeted therapy: A new horizon in malignant pleural mesothelioma management. In: Horizons in Cancer Research, Nova Science Publishers, Inc., Hauppauge, NY, Editor: Hiroto S. Watanabe.2017; Volume 64: Chapter 6:129-162.

Hatano R, Ohnuma K, Yamada T, Okamoto T, Komiya E, Otsuka H, Itoh T, Yamazaki H, Iwao N, Kaneko Y, Dang NH, Morimoto C. The use of the humanized anti-CD26 monoclonal antibody YS110 as a novel targeted therapy for refractory cancers and immune disorders. In: Advances in Medicine and Biology, Nova Science Publishers, Inc., Hauppauge, NY, Editor: Leon V. Berhardt.2018;Volume 129: Chapter 1:1-44.

Ohnuma K, Hatano R, Komiya E, Otsuka H, Itoh T, Iwao N, Kaneko Y, Yamada T, Dang NH, Morimoto C. A novel role for CD26/dipeptidyl peptidase IV as a therapeutic target. Front Biosci.2018;23:1754-1779.

Okamoto T, Yamazaki H, Hatano R, Yamada T, Kaneko Y, Xu CW, Dang NH, Ohnuma K, Morimoto C. Targeting CD26 suppresses proliferation of malignant mesothelioma cell via downmodulation of ubiquitin-specific protease 22. Biochem Biophys Res Commun. 2018; 504(2): 491-498

Nishida H, Hayashi M, Morimoto C, Sakamoto M, Yamada T.CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma. Blood Cancer J. 2018; 8(11): 99

Ohnuma K, Hatano R, Komiya E, Otsuka H, Itoh T, Iwao N, Kaneko Y, Yamada T, Dang NH, Morimoto C. A novel role for CD26/dipeptidyl peptidase IV as a therapeutic target. Front Biosci(Landmark Ed). 2018;23:1754-1779

Ohnuma K, Hatano R, Dang NH, Morimoto C. Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy. Mod Rheumatol. 2018;Oct 4:1-32[Epub ahead of print]

Itoh T, Hatano R, Komiya E, Otsuka H, Narita Y, Aune TM, Dang NH, Matsuoka S, Naito H, Tominaga M, Takamori K, Morimoto C, Ohnuma K. Biological effects of IL-26 on T cell-mediated skin inflammation including psoriasis. J Invest Dermatol. 2019; 139(4): 878-889

Santos MF, Rappa G, Karbanova J, Vanier C, Morimoto C, Corbeil D, Lorico A. Anti-human CD9 antibody Fab fragment impairs the internalization of extracellular vesicles and the nuclear transfer of their cargo proteins. J Cell Mol Med. 2019; 23(6): 4408-4421

Mezawa Y, Daigo Y, Takano A, Miyagi Y, Yokose T, Yamashita T, Morimoto C, Hino O, Orimo A. CD26 expression is attenuated by TGF-β and SDF-1 autocrine signaling on stromal myofibroblasts in human breast cancers. Cancer Med. 2019; 8(8): 3936-3948

Hatano R, Yamada T, Madokoro H, Otsuka H, Komiya E, Itoh T, Narita Y, Iwata S, Yamazaki H, Matsuoka S, Dang NH, Ohnuma K, Morimoto C. Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens. PLoS One. 2019; 14(6): e0218330

Hatano R, Itoh T, Otsuka H, Okamoto S, Komiya E, Iwata S, Aune TM, Dang NH, Kuwahara-Arai K, Ohnuma K, Morimoto C. Characterization of novel anti-IL-26 neutralizing monoclonal antibodies for the treatment of inflammatory diseases including psoriasis. MAbs. 2019; 11(8): 1428-1442

Hayashi M, Madokoro H, Yamada K, Nishida H, Morimoto C, Sakamoto M, Yanagawa H, Yamada T. Novel Antibody-Drug Conjugate with Anti-CD26 Humanized Monoclonal Antibody and Transcription Factor IIH(TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis. Cancers (Basel). 2019; 11(8): E1138

Takeda T, Ohe Y, Horinouchi H, Hida T, Shimizu J, Seto T, Nosaki K, Kishimoto T, Miyashita I, Yamada M, Kaneko Y, Morimoto C, Nakagawa K. Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma. Lung Cancer 2019 Sep 16; 137:64-70

Sato T, Tatekoshi A, Takada K, Iyama S, Kamihara Y, Jawaid P, Rehman MU, Noguchi K, Kondo T, Kajikawa S, Arita K, Wada A, Murakami J, Arai M, Yasuda I, Dang NH, Hatano R, Iwao N, Ohnuma K, Morimoto C. DPP8 is a novel therapeutic target for multiple myeloma. Sci Rep. 2019; 9(1):18094

Corridoni　D, Antanaviciute A, Gupta T, Fawkner-Corbett D, Aulicino A, Jagielowicz M, Parikh K, Repapi E, Taylor S, Ishikawa D, Hatano R, Yamada T, Xin W, Slawinski H, Bowden R, Napolitani G, Brain O, Morimoto C, Koohy H, Simmons A. Single-cell atlas of colonic CD8+ T cells in ulcerative colitis. Nat Med. 2020;26(9):1480-1490

Kaneko Y, Hatano R, Hirota N, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcman G, Valleix F, Podoll T, Umezawa Y, Takao S, Iwata S, Hosono O, Taguchi T, Yamada T, Dang NH, Ohnuma K, Angevin E, Morimoto C. Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.　 Biomark Res. 2021;9(1):21

Itoh T, Hatano R, Horimoto Y, Yamada T, Song D, Otsuka H, Shirakawa Y, Matsuoka S, Iwao N, Aune TM, Dang NH, Kaneko Y, Okumura K, Morimoto C, Ohnuma K. IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells. Cell Death Dis. 2021; 12(6): 520

Pan K, Ohnuma K, Morimoto C, Dang NH. CD26/Dipeptidyl Peptidase IV and Its Multiple Biological Functions. Cureus. 2021; 13(2): e13495

Ohmachi-Ono A, Yamada S, Uno S, Tamai M, Soga K, Nakamura S, Udagawa N, Nakamichi Y, Koide M, Morita Y, Takano T, Itoh T, Kakuta S, Morimoto C, Matsuoka S, Iwakura Y, Tomura M, Kiyono H, Hachimura S, Nakajima-Adachi H. Effector memory CD4 + T cells in mesenteric lymph nodes mediate bone loss in food-allergic enteropathy model mice, creating IL-4 dominance. Mucosal Immunol. 2021; 14(6):1335-1346

Komiya E, Mitsutoshi Tominaga M, Hatano R, kamikubo Y, Toyama S, Sakairi H, Hond K, Itoh T, Kamata Y, Tsurumachi M, Kishi R, Ohnuma K, Sakurai T, Morimoto C, Takamori K. Peripheral endomorphins drive mechanical alloknesis under the enzymatic control of CD26/DPPIV. J Allergy Clin Immunol. 2022;149(3):1085-1096

Hatano R, Itoh T, Otsuka H, Saeki H, Yamamoto A, Song D, Shirakawa Y, Iyama S, Sato T, Iwao N, Harada N, Aune TM, Dang NH, Kaneko Y, Yamada T, Morimoto C, Ohnuma K. Humanized anti-IL-26 monoclonal antibody as a novel targeted therapy for chronic graft-versus-host disease. Am J Transplant. 2022; 22(12): 2804-2820. doi: 10.1111/atj.17178. Epub 2022 Sep 9.

Santos MF, Rappa G, Fontana S, Karbanova J, Aalam F, Tai D, Li Z, Pucci M, Alessandro R, Morimoto C, Corbeil D, Lorico A. Anti-Human CD9 Fab Fragment Antibody Blocks the Extracellular Vesicle-Mediated Increase in Malignancy of Colon Cancer Cells. Cells. 2022; 11(16):2474. doi: 10.3390/cells11162474.

Kobayashi S, Fugo K, Hatano R, Yamazaki K, Morimoto C, Terawaki H. Anti-glomerular Basement Membrane Disease Concomitant with MPO-ANCA Positivity Concurrent with High Serum Levels of Interleukin-26 Following Coronavirus Disease 2019 Vaccination. Intern Med. 2023; 62(7): 1043-1048. Doi: 10.2169/internalmedicine.1027-22.

Koyanagi Y, Kawasaki T, Kasuya Y, Hatano R, Sato S, Takahashi Y, Ohnuma K, Morimoto C, Dudek SM, Tatsumi K, Suzuki T. Functional roles of CD26/DPP4 in bleomycin-induced pulmonary fibrosis. Physiol Rep. 2023; 11(6): e15645. Doi: 10.14814/phy2.15645.

Kikuchi S, Wada A, Kamihara Y, Okazaki K, Jawaid P, Rehman MU, Kobayashi E, Susukida T, Minemura T, Nabe Y, Iwao N, Ozawa T, Hatano R, Yamada M, Kishi H, Matsuya Y, Mizuguchi M, Hayakawa Y, Dang NH, Sakamoto Y, Morimoto C, Sato T. DPP8 Selective Inhibitor Tominostat as a Novel and Broad-Spectrum Anticancer Agent against Hematological Malignancies. Cells. 2023; 12(7): 1100. Doi: 10.3390/cells12071100.

研究者

教育活動

【学校法人順天堂】研究者情報データベース

研究業績詳細

森本 幾夫（モリモト チカオ）

森本幾夫（モリモトチカオ）